InspireMD Inc
NASDAQ:NSPR
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| IL |
|
InspireMD Inc
NASDAQ:NSPR
|
75.9m USD |
Loading...
|
|
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
65.4B USD |
Loading...
|
|
| JP |
|
Hoya Corp
TSE:7741
|
9.8T JPY |
Loading...
|
|
| CH |
|
Alcon AG
SIX:ALC
|
31.8B CHF |
Loading...
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
111B DKK |
Loading...
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.1B USD |
Loading...
|
|
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
6.3B USD |
Loading...
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
5B GBP |
Loading...
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
41.1B CNY |
Loading...
|
|
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
833.6B JPY |
Loading...
|
|
| US |
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
4.9B USD |
Loading...
|
Market Distribution
| Min | -11 239.1% |
| 30th Percentile | 17.6% |
| Median | 29.8% |
| 70th Percentile | 50.4% |
| Max | 208.2% |
Other Profitability Ratios
InspireMD Inc
Glance View
InspireMD, Inc. operates as a medical device company, which engages in the development and commercialization of the stent platform technology for the treatment of complex vascular and coronary disease. The firm is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The company markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. The company is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for InspireMD Inc is 24.9%, which is above its 3-year median of 24.7%.
Over the last 3 years, InspireMD Inc’s Gross Margin has increased from 21.9% to 24.9%. During this period, it reached a low of 21.1% on Jun 30, 2025 and a high of 29.1% on Dec 31, 2023.
